Alto Neuroscience (NYSE: ANRO) CFO sells shares under trading plan

What happened

Alto Neuroscience, Inc. (NYSE: ANRO) said President and CFO Nicholas Conrad Smith sold 134,886 shares from 09/29/2026 to 09/30/2026. The shares sold for $25.78 to $26.87 each, or about $3.57 million. After the sales, Smith held 24,060 shares.

The filing says the trades were made under a Rule 10b5-1 trading plan adopted on June 30, 2026. Table I shows 110,830 shares sold on 09/29/2026, then 23,170 shares and 886 shares sold on 09/30/2026. The filing says the 09/29/2026 sale used a weighted average price of $26.5826, with trades from $26.5513 to $26.5902. On 09/30/2026, Smith also exercised 24,056 options before selling 23,170 shares and 886 shares later that day.

The same form also shows option exercises tied to 56,455 shares, 54,375 shares and 24,056 shares at a $2.35 exercise price.

Key numbers

Metric	Latest	Change	Source
Shares sold	134,886 shares		SEC Form 4
Sale value	about $3.57 million		SEC Form 4
Sale price range	from $25.78 to $26.87 per share		SEC Form 4
Shares held after	24,060 shares		SEC Form 4

Read more: Alto Neuroscience (ANRO) stock analysis and investment case

Why it matters

OptimistFi's case is that Alto is a clinical-stage psychiatry option, so trial progress matters before cash burn forces unfavorable dilution. By that view, this filing does not change the case. OptimistFi's calculation shows the 134,886 shares sold were about 84.9% of Smith's pre-trade holding.

The remaining 24,060 shares give investors a clear post-trade baseline for later Form 4 checks. The Rule 10b5-1 plan is the main caveat, since the filing links the sale to a prearranged trading plan adopted on June 30, 2026. The option exercises in the same form show Smith also moved shares into common stock before selling part of the position.

Browse: stock research on every company OptimistFi covers

What's next

The next quarterly report is the next dated check on whether the reported 24,060-share stake changes again. Any later Form 4 will show whether the remaining position changes again. A steady holding would support the view that this was a planned reduction.

More selling would point to a deeper trim. A larger reported stake would weaken that reading. For now, the form sets a dated baseline for the insider's holdings and the plan status.

More from OptimistFi